Nicholas Saraceno, Editor

KOLs in the sector examine the current dealmaking landscape, including the status of available capital.

Merck seeks approval for Keytruda (pembrolizumab) plus chemotherapy with carboplatin and paclitaxel for patients with primary advanced or recurrent endometrial carcinoma, alongside chemotherapy (carboplatin and paclitaxel).

The FDA set a Prescription Drug User Fee Act date during Q4 of 2024 for the biologics license application for datopotamab deruxtecan in patients with previously treated advanced nonsquamous non-small cell lung cancer.

Researchers find that a thorough evaluation of drug spending and value can lead to a better allocation of healthcare resources.

Researchers evaluate a potential association between the use of phosphodiesterase type 5 inhibitors for erectile dysfunction and a reduced risk of Alzheimer disease.

The biopharma company’s Phase 3 trial for its acoramidis product generated statistically significant results.

JAMA study evaluates a potential correlation between new recreational cannabis laws and a possible reduction in synthetic opioid deaths.

In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Study highlights how AI can identify trends and connections that can predict how new patients might respond to therapies.

Although medications such as Mounjaro and Zepbound have shown efficacy in helping individuals lose weight, there are not yet enough results to fully support these claims.

Over the past 15 years, on average, racial and ethnic diversity in multiple US regions has increased by 1% to 5%.

Researchers highlight steps to be taken in the European Union to manage the challenge of ongoing drug shortages.

For manufacturers who participate in the 340B program, costs have increased because they are required to provide steep discounts on their drugs at levels far below private market prices.

IQVIA report explores why these shortages are increasing, and how they can be mitigated.

Dozens of companies are selling stem cell treatments and exosome therapies that have not been approved for use or authorized for emergency use by the FDA.